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An immunogenic peptide (GP2) derived from HER-2/
neu binds to HLA-A2.1 very poorly. Some altered-pep-
tide ligands (APL) of GP2 have increased binding affin-
ity and generate improved cytotoxic T lymphocyte
recognition of GP2-presenting tumor cells, but most do
not. Increases in binding affinity of single-substitution
APL are not additive in double-substitution APL. A com-
mon first assumption about peptide binding to class I
major histocompatibility complex is that each residue
binds independently. In addition, immunologists inter-
ested in immunotherapy frequently assume that anchor
substitutions do not affect T cell receptor contact resi-
dues. However, the crystal structures of two GP2 APL
show that the central residues change position depend-
ing on the identity of the anchor residue(s). Thus, it is
clear that subtle changes in the identity of anchor resi-
dues may have significant effects on the positions of the
T cell receptor contact residues.
Class I major histocompatibility complex (MHC)1 proteins
bind short peptides (8–11 amino acids) endogenously derived
either from host or pathogen. These peptides bind to newly
formed class I molecules in the endoplasmic reticulum. Peptide
binding appears to be the final step in assembly of the complex
(1). The complexes are presented to circulating T cells at the
plasma membrane where clonotypic T cell receptors (TCR) on
the surface of circulating cytotoxic T lymphocytes (CTL) may
recognize the peptide-MHC complex (pMHC) and kill the pre-
senting cell. An unaltered cell presents a population of self-
peptides bound to class I MHC and is, for the most part, ignored
by circulating T cells. However, cells infected by a virus or
altered by neoplastic transformation present different peptides
bound to class I MHC at the cell surface. These altered cells are
recognized by clonotypic TCR on CD81 T cells, and the T cells
lyse the presenting cell. This action removes either the source
of virus replication or the potential tumor (2).
The class I MHC molecule is a ternary complex consisting of
a polymorphic heavy chain, a noncovalently associated light
chain b2-microglobulin, and a small peptide (8–10 residues)
(3–8). The peptide binding cleft is formed by the a1 and a2
domains of the heavy chain. For effective CD81 T cell re-
sponses, class I MHC molecules must bind many peptides of
diverse sequence in sufficient abundance for long periods of
time. Typical half-lives of immunodominant peptides are
greater than 20 h at 37 °C (9, 10). Peptides bind to class I MHC
primarily through the invariant peptidic termini (11–13). In
addition, the polymorphic residues within the peptide binding
groove create specificity pockets that select specific amino acids
in the peptide (14, 15). The specificity pockets for HLA-A2.1
(A2) are found close to the peptidic termini and are comple-
mentary in shape and charge to residues 2 (P2) and the last
residue of the peptide (PV). The specificity pockets play a large
role in binding affinity to A2 (16, 17) but not to all class I MHC
(18). The result of this set of interactions in A2 is the binding of
the ends of the peptide, leaving the center relatively free of
interactions. The center of the peptide bulges out of the peptide
binding cleft, and the main chain rarely traverses the same
path in two different peptides (19). The co-crystal structures of
class I MHC and TCR show that the means of engagement
between pMHC and TCR are conserved (20–24). The TCR
binds in a diagonal manner with the TCR a chain interacting
with the carboxyl end of the MHC a2 helix and the TCR b chain
interacting with the carboxyl end of the MHC a1 helix. The
CDR3 regions of the TCR a and b chains interact with the
center of the peptide (P5–P7 depending on the peptide) (25, 26).
Two aspects about peptide binding to class I MHC are ex-
plored by the experiments presented here. The first aspect is an
assumption that each amino acid in the peptide binds inde-
pendently of one another to enhance or detract from the overall
binding affinity. Using this assumption, a popular algorithm
was designed to predict peptide epitopes that bind well. This
algorithm is predicated on the assumption that each residue
binds independently (27). Although this algorithm predicts
many good binding peptides from proteins of interest (28–32),
for unknown reasons it fails to predict accurately the results of
single amino acid substitutions. The second aspect of peptide
binding explored here is that residues at the anchor positions
do not affect the conformation of residues elsewhere in the
peptide. If one assumes that each residue binds independently,
homologous substitutions would be the best choice to amplify
and activate T cells specific for the parental antigen (33–35).
The clear choice for modification is the anchor residues because
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they point into the binding cleft and are restricted in space by
the specificity pockets. Thus, the conformation flexibility of the
peptide backbone should be limited, and any alterations in the
structure caused by the anchor substitution would be expected
to be local and small. This idea has been used to design pep-
tides with increased affinity for class I MHC to enhance CTL
stimulation. This approach has been successful in some cases
(36–38) and varied in others (39). T cells stimulated using
altered-peptide ligands (APL) are not necessarily the same
population of T cells (40). This change in reactivity may be a
result of interactions between the single amino acid changes
and the MHC or between the substitutions and the other amino
acids within the peptide. Our studies provide an explanation
for the instances in which alteration reduces or eliminates
reactivity. These data show that substitutions at the anchor
positions can directly alter the conformation of the residues at
the center of the peptide and conversely that substitutions in
the center can cause large changes at the termini.
We examined binding of a selection of known immunologi-
cally recognized peptide ligands from the tyrosine kinase fam-
ily member HER-2/neu to the class I MHC molecule A2. HER-
2/neu is overexpressed in ;30% of patients with breast cancer
and similarly in all adenocarcinomas examined. Despite the
presence of CTL that recognize these peptides bound to A2, the
tumors are not eliminated. These HER-2/neu-derived peptides
contain appropriate anchor residues but still bind poorly to A2
molecules (41). One proposed explanation for inefficient tumor
killing is that the peptide antigens bind poorly to A2, and these
complexes are not stable enough to be recognized well by HER-
2/neu peptide-specific CTL. Our long term goal is to design high
affinity APL for cancer immunotherapy. We have examined
binding of one of these poor-binding peptides, GP2 (IISAV-
VGIL), to design a ligand for immunotherapy. The crystallo-
graphic structure of GP2 co-crystallized with A2 (A2GP2) shows
that the center of the peptide is disordered and apparently does
not make stabilizing contacts with the peptide binding cleft
(41). GP2 has anchor residues that are present in high affinity
peptides (isoleucine at position 2 and leucine at position 9) (42).
Substitution of these anchor residues with amino acids most
preferred by A2 increased the binding affinity, but not signifi-
cantly (41).
Based on the crystallographic structure of GP2 bound to A2,
we designed a new APL in which we substituted the position 5
(P5) valine with leucine (V5L). We hypothesized that the larger
leucine would fit into a hydrophobic pocket in the peptide
binding cleft under the a2 a helix where the smaller valine
could not reach. We synthesized a series of peptides that in-
cluded the V5L substitution in combination with our anchor
substitutions to maximize binding affinity. Measurements of
binding affinity and peptide off-rates showed that the enhance-
ment in binding of double-substitution peptides was not the
sum of the increases from the single-substitution peptides. We
interpreted this to mean that there are interactions between
residues in the peptide or changes in the peptide structure. To
understand these interactions, the crystallographic structures
of A2 bound to the GP2 variants I2L/V5L (A2I2L/V5L) and I2L/
V5L/L9V (A2I2L/V5L/L9V) were determined. These structures
show that the peptide residues interact and that the TCR
contact residues alter their positions depending on the identity
of the anchor residue. Therefore, homologous substitutions
anywhere in the peptide may have large unintended conse-
quences in T cell recognition.
MATERIALS AND METHODS
Peptides—The peptides used in this study are listed in Table I. All
peptides were synthesized by the Peptide Synthesis Facility at the
University of North Carolina, Chapel Hill. The peptides were purified to
greater than 95% purity as confirmed by reversed phased chromatog-
raphy and matrix-assisted laser desorption ionization time-of-flight
mass spectrometry. Peptides were dissolved in 100% dimethyl sulfox-
ide, 10 mg/ml by weight. Final concentrations were determined by
amino acid analysis by the Protein Chemistry Laboratory in the De-
partment of Chemistry, University of North Carolina, Chapel Hill.
Preparation of HLA-A2.1-Peptide Complexes—HLA-A2.1-peptide
complexes were prepared as described previously (43). Briefly, residues
1–275 of A2 and residues 1–99 of b2-microglobulin were produced in
Escherichia coli as inclusion bodies. Peptide, solubilized b2-microglobu-
lin, and A2 heavy chain, solubilized in 8 M urea, were rapidly diluted
into folding buffer (100 mM Tris, pH 8.0, 400 mM L-Arg, 10 mM GSH, 1
mM GSSG, and protease inhibitors) at molar ratios of 10:2:1, respec-
tively. The solution was incubated at 10 °C for 36–48 h, concentrated
by ultrafiltration (Amicon), and purified by high pressure liquid chro-
matography gel filtration (Phenomenex, BioSep-SEC-S2000).
Thermal Denaturation Studies—The thermal denaturation proper-
ties of A2-peptide complexes were determined as described previously
(12). Purified A2-peptide complexes were exchanged into a 10 mM
KH2/K2HPO4 buffer, pH 7.5, and adjusted to final concentration of 4–12
mM. Thermal denaturation curves (melting curve) of MHC-peptide com-
plexes were recorded by monitoring the change in circular dichroic (CD)
signal at 218 nm as a function of temperature from 4 °C to 95 °C on an
AVIV 62-DS spectropolarimeter (Aviv Associates, Lakewood, NJ). The
final melting curves were the average of at least three measurements
for each complex. Tm values were calculated as the temperature at
which 50% of the complexes are unfolded.
Cell Surface Stabilization Assays—The ability of peptide to stabilize
A2 on the surface of T2 (ATCC CRL-1992) cells was determined as
described previously (10). Briefly, T2 cells (2.5 3 105 cells/well) were
incubated overnight in AIM V medium (Life Technologies, Inc.) with
varying concentrations of peptide. The following morning, cells were
stained with the A2-specific monoclonal antibody BB7.2. After two
washes with wash buffer (1 3 phosphate-buffered saline, 2% fetal
bovine serum, 0.1% sodium azide), the cells were incubated for 30 min
at 4 °C with a 1:50 dilution of fluorescein isothiocyanate-conjugated
goat anti-mouse IgG antibody (Southern Biotechnologies). Fluorescence
was detected on a FACScan (Becton-Dickinson, Lincoln Park, NJ). The
data were then normalized to the mean channel fluorescence for the
index peptide ML at 50 mM. The ML peptide (MLLSVPLLL) is derived
from the signal sequence of calreticulin and has a hydrophobicity sim-
ilar to that of the peptides used in this study.
Cell Surface Half-life Assay—The half-life of A2-peptide complexes
on the surface of T2 cells was determined as described previously (10).
Briefly, T2 cells (8 3 105 cells/well) were incubated overnight in AIM V
medium with 50 mM peptide. Cells were incubated in RPMI-1650, 10%
fetal calf serum, 10 mg/ml brefeldin A for 1 h. Because this concentra-
tion of brefeldin A is toxic to the cells if they are exposed for long periods
of time, the cells were transferred and maintained at 0.5 mg/ml through
FACScan analysis. Cells were then stained with BB7.2 at various time
TABLE I
Binding data of GP2 variant peptides to A2
Residues substituted with respect to wild type peptide are shown in
boldface. Tm is the temperature (°C) at which 50% of protein is dena-
tured as measured by circular dichroism. Kr is the relative binding
constant as determined by the T2 cell surface assembly assay. t1/2 is the
half-life of A2-peptide complexes (in hours) as determined by the T2 cell
surface stability assay. The error in the Tm is the sum of machine and




HN654–662c IISAVVGIL 36.4 .50 0.35
I2Lb ILSAVVGIL 42.2 22.9 1.76
L9Vb IISAVVGIV 38.8 .50 0.69
V5L IISALVGIL DNF .50 ,0.20
I2L/L9Vb ILSAVVGIV 42.5 10.0 2.48
I2L/V5L ILSALVGIL 39.0 49.3 1.06
V5L/L9V IISALVGIV 38.8 .50 1.18
I2L/V5L/L9V ILSALVGIV 39.5 17.5 1.08
MLb MLLSVPLLL 52.5 1.8 19.53
a DNF, did not fold in vitro so a Tm could not be derived.
b .50 means that the concentration to yield 50% of ML fluorescence
is greater than 50 mM. Kr is defined as concentration of peptide in mM
which yields 50% mean channel fluorescence (MCF) compared with the
maximum fluorescence of the control peptide (ML) at 50 mM. The Kr
value given for ML is the concentration that yields 50% MCF.
c Values taken from Ref. 41.
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points and analyzed by flow cytometry as described above. The mean
fluorescence for the peptide at each time point minus the mean fluo-
rescence of T2 cells incubated without exogenous peptide was calcu-
lated and normalized to the maximum level of fluorescence for each
APL (at t 5 0).
Crystallization, Data Collection, and Data Processing—Crystals
were grown by the hanging drop vapor diffusion method. Crystals were
grown from 14–20% polyethylene glycol 8000, 25 mM MES, pH 6.5, for
both A2I2L/V5L/L9V and A2I2L/V5L over the course of 2 days by microseed-
ing. Crystallographic data for both structures were collected at 100 K in
house (University of North Carolina Macromolecular Crystallography
Facility) on a RIGAKU RU200 equipped with RAXIS IIC imaging plate
detector and Oxford Cryostream. Data were collected from a single
crystal of A2I2L/V5L/L9V and from two crystals of A2I2L/V5L. Data for both
structures were integrated with DENZO and intensities scaled with
SCALEPACK (44). The statistics for each data set for both structures
are given in Table II.
Structure Determination and Refinement—Both structures were de-
termined by molecular replacement using AMoRe (45) within the CCP4
program suite (46). The crystals are triclinic, space group P1 with two
molecules per asymmetric unit.The A2-hepatitis peptide complex (PDB
accession code 1HHH) was used as the search model (47). The search
model was divided into three pieces: the peptide binding superdomain
(a1a2), the a3 domain, and the b2-microglobulin light chain. Rigid body
refinement was performed in CNS (48–50) leaving the a1a2, a3, and
b2-microglobulin as three separate rigid bodies. Nine rounds of tor-
sional dynamics refinement with CNS and manual intervention with O
(51) were performed. NCS restraints for regions not involved in crystal
contacts were maintained, and a model was built for one copy in the
asymmetric unit and the second generated using the NCS operators. To
reduce model bias, peptide was not included in the initial three rounds
of refinement. The electron density maps were generated using DM (46)
using the functions for 2-fold noncrystallographic averaging, histogram
matching and solvent flattening. 144 water molecules for A2I2L/V5L/L9V
and 35 waters for A2I2L/V5L were added to the structure using the
program ARP (52) combined with REFMAC and confirmed by visual
inspection of the electron density maps. Refinement statistics for each
model are given in Table II.
RESULTS
Stabilization Derived from Individual Anchor Substitutions
Is Not Additive in Double-substitution Peptides—Previous
studies had shown that substitutions at anchor positions in-
creased thermal stability of A2GP2 (41). The thermal stability of
the peptides given in Table I shows that the individual anchor
substitutions generate increases in Tm from 2.4 °C (A2
L9V) to
5.8 °C (A2I2L). If stabilization of binding were the sum of the
increases, the double substitution should generate 8.4 °C in-
creased thermal stability, but the observed difference is 6.1 °C
(A2I2L/L9V), suggesting that the mechanism of stabilization is
not entirely peptide position-independent. The T2 assays of
binding and kinetics of dissociation confirm that there is an
improvement in the double-anchor substitution peptide. The
binding is better (smaller Kr), and dissociation is slower (longer
t/2) for the double anchor variant, but the expected changes in
the values cannot be examined for the Kr because we cannot
measure the value for A2L9V.
A Substitution at the Center of the Peptide Designed to Im-
prove Binding Affinity Actually Reduces Binding Affinity by
Itself and Interacts with Anchor Substitutions Unexpectedly—
Based on the crystallographic structure of GP2 bound to A2
(41), we designed a new peptide in hopes that it would bind
with higher affinity and reduce the disorder in the center of the
peptide. In the structure, a large hydrophobic pocket was found
near the P5 valine under the a2 a helix. We hypothesized that
a leucine in place of the valine at position 5 in the center of
peptide would be more complementary to the size and shape of
the pocket. The V5L peptide was synthesized and tested for
binding affinity using T2 and CD assays. As can be seen in
Table I, the V5L peptide actually binds worse than does GP2.
In fact, it binds so poorly that A2V5L cannot be isolated in
sufficient quantity to use in CD or structural studies. Combi-
nations of anchor substitutions and the V5L substitutions were
synthesized to determine whether better anchors would facili-
tate use of this hydrophobic pocket by the leucine at P5. It
quickly became clear that these substituted residues were in-
teracting in unexpected ways. For example, the Tm of A2
L9V is
38.8 °C, and the Tm of A2
V5L/L9V is also 38.8 °C, suggesting that
the V5L substitution makes no difference to the stability of the
complex. However, as described above, V5L alone binds with
lower affinity compared with GP2, suggesting that it detracts
from binding affinity. Confirming this, the Tm for the A2
I2L/V5L
double substitution is 39.0 °C, which is 3.2 °C lower than the
single substitution I2L. Similarly, the Tm for the triple substi-
tution A2I2L/V5L/L9V is 39.5 °C, which is 3.0 °C lower than the
double substitution A2I2L/L9V. These unexpected interactions
as measured by CD are substantiated by the binding assays
using T2 cells (Fig. 1 and Table I). To understand these inter-
actions, we decided to determine the crystal structures of some
of these complexes.
The Crystallographic Structures of A2I2L/V5L/L9V and A2I2L/V5L
Confirm That the Individual Residues Interact—The molecular
replacement solutions for the two complexes were unambigu-
ous and gave correlation coefficients of 79% for A2I2L/V5L/L9V
and 75% for A2I2L/V5L using 1HHH as a search model (47).
These initial models were refined in CNS (48–50), and peptide
was omitted during the first three stages of refinement (until
the Rwork was below 30%) in both structures to reduce model
TABLE II





Space group Pl Pl
Cell dimensions a 5 50.21 Å a 5 49.95 Å
b 5 62.32 Å b 5 62.93 Å
c 5 74.66 Å c 5 74.65 Å
a 5 82.15° a 5 82.07°
b 5 76.38° b 5 76.50°
g 5 78.33° g 5 78.04°
Molecules/AU 2 2
Rmerge (%)
b 9.5 (29.3) 5.5 (18.0)
^I/s& 4.73 (2.4) 14.07 (5.7)
Unique reflections 33,403 38,096
Total observations 114345 214687




c 26.3% (31,833) 24.8% (36,189)
Rfree 29.0% (1,670) 28.6% (1,907)
Errord 0.31 Å 0.26 Å
Non-hydrogen atoms 6,294 6,292
^RS fit&e 78.4% 80.7%
Average B factor 21.3 Å 19.1 Å
No. of waters 35 144
RMSD
Bonds 0.008 Å 0.007 Å
Angles 1.3 ° 1.3 °
Ramachandran
Most favorable 90.3% 91.6%
Additionally allowed 9.0% 8.1%
Generously allowed 0.7 0.3%
Disallowed 0.0% 0.0%
a Number in parentheses refers to the highest resolution shell. It is
2.44–2.3 Å for A2I2L/V5L and 2.39–2.25 Å for A2I2L/V5L/L9V.
b Rmerge 5 Shkl Si uIi 2 ^I&u / Shkl Si Ii, where Ii is the observed intensity
and ^I& is the average intensity of multiple observations of symmetry
related reflections.
c R 5 Shkl iFobsu 2 k uFcalu u / Shkl uFobsu, where Rfree is calculated for a
randomly chosen 5% of reflections, Rwork is calculated for the remaining
95% of reflections used for structure refinement. Numbers in parenthe-
ses refer to the number of structure factors used in the measurements.
d Error is the mean coordinate error estimate based on maximum
likelihood measurements (46).
e ^RS fit& is the average real space fit of all atoms on an electron
density map from DM with 2-fold non-crystallographic averaging, his-
togram matching, and solvent flattening.
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bias. Density modification was performed with DM (46) to
generate unbiased averaged electron density maps. The final
structures are well defined in the electron density maps with
average real space correlation coefficients of 78.4 and 80.7%
with all fragments of A2I2L/V5L and A2I2L/V5L/L9V. The final
models have an overall Rfree of 29.0% from 50 to 2.3 Å for
A2I2L/V5L and 28.6% from 50 to 2.25 Å for A2I2L/V5L/L9V with
good stereochemistry and no residues in the disallowed regions
of a Ramachandran plot (Table II).
In both structures, the positions of the peptidic termini are
unambiguous. However, the electron density at the center of
the peptide is not well defined in both I2L/V5L and I2L/V5L/
L9V peptides as was seen in the GP2 peptide (41). The peptides
in the two molecules in the asymmetric unit are not equivalent
in these structures, demonstrating some of the dynamics that
are known to be in the system. These differences in the pep-
tides are not caused by crystal contacts.
A2I2L/V5L Structure—The electron density for the I2L/V5L
peptide in molecule 2 (MOL2) in the asymmetric unit is broken
at valine at P6 and glycine at P7 (Fig. 2B). This is similar to
what was observed in the GP2 peptide in the A2GP2 crystal
structure (41). However, in molecule 1 (MOL1) the peptide
density is continuous over the main chain of the peptide (Fig.
2A). However, the side chain for residue 6 is undefined, and the
temperature factors are higher for the central residues in the
peptide, demonstrating that the central residues in molecule 1
have greater disorder than the termini. The orientation of side
chain of leucine at P5 is different between the two NCS sym-
metry-related molecules of A2I2L/V5L (a rotation of ;83o of the
Ca-Cb bond), and they refine to these different positions re-
gardless of the starting position before CNS refinement. Al-
though there is not sufficient density to have absolute confi-
dence in the position of the valine at position 6, there is
sufficient electron density to strongly suggest that they orient
in opposite directions. It appears that the P6 valine in molecule
2 points diagonally toward the a2 a helix and down into the
cleft, and the P6 valine in molecule 1 points toward the a1 a
helix.
A2I2L/V5L/L9V Structure—Although there are differences in
the electron density for the peptides in molecules 1 and 2 in the
asymmetric unit of the A2I2L/V5L/L9V, the differences are much
smaller than those observed for the two copies of A2I2LV5L and
do not affect the orientations of the peptide in either model.
There is a break in the electron density at valine at P6 and
glycine at P7 in both symmetry-related molecules as in the
A2GP2 structure, and the orientation of valine at P6 cannot be
interpreted in either molecule (Fig. 2, C and D). The electron
density for the leucine at P5 is not well defined, but the direc-
tion of the electron density clearly indicates the orientation of
the side chain is toward solvent in both copies in the asymmet-
ric unit.
DISCUSSION
For an effective immune response, it is necessary that class
I MHC present antigenic peptides for long periods of time on
the cell surface to allow detection of these complexes by circu-
lating T cells (53). Many tumor cells appear to escape the
immune response because antigenic peptides do not bind well
to the class I MHC molecule that present them (54, 55). If
peptide does not bind efficiently to the MHC molecule, circu-
lating T cells will not recognize the pMHC complex, and cells
presenting them will not be eliminated. To enhance the binding
cells were removed at the indicated times and the remaining A2-peptide
on the cells determined by incubating with BB7.2. Error bars are the
S.E.
FIG. 1. Thermal denaturation as measured by circular dichro-
ism shows unpredicted interactions between residues in the
peptide. Panel A, thermal denaturation curves of complexes of A2
bound to GP2 variants. Each curve is the average of three independent
experiments using 4–12 mM protein. The Tm is the temperature at
which 50% of the complexes are unfolded. The error associated with this
type of measurement is the sum of the error in the temperature con-
troller and the curve fitting error. This is ;0.5 °C for each complex.
Panel B, cell surface A2 was stabilized on T2 cells by the addition of the
indicated amounts of peptide. The amount of A2-peptide on the cell
surface was measured by flow cytometry using the A2-specific mono-
clonal antibody, BB7.2. Panel C, the rate of loss of cell surface A2-
peptide complexes was measured by treating the peptide-pulsed cells
(as in panel B) with brefeldin A to halt vesicular transport. Aliquots of
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affinity of antigenic peptides to class I MHC molecules, it is
necessary to understand the forces that determine the binding
affinity of peptide to class I MHC. We have examined a poor-
binding peptide antigen derived from the tyrosine kinase fam-
ily member HER-2/neu.
Our initial studies were focused on improving the binding
affinity of GP2 to A2 by producing variants of GP2 at the
anchors. The long term goal is to use the variant peptide of GP2
to stimulate a vigorous GP2-specific CTL response in the can-
cer patient or as a vaccine in a healthy person. Because the
prevalent belief is that each amino acid acts independently to
generate positive or negative effects to binding energy (27), we
expected to be able to generate the best binder in a stepwise
fashion; that is, we saw an increase in thermal stability with
I2L and L9V peptides bound to A2, and we expected to be able
to add them together to get the best binding peptide (I2L/L9V).
The data showed that the increased affinity generated by this
approach was not as great as we expected.
We determined the crystal structure of A2GP2 and during our
analysis of the structure, and we hypothesized that if the valine
at P5 was a leucine, it could take advantage of a hydrophobic
pocket under the a2 a helix. However, our data clearly show
that this substitution also did not improve binding affinity.
More surprisingly, we saw that combinations of anchor substi-
tutions with the V5L substitution resulted in unexpected
changes to the thermal stability of the complex. In one case, the
substitution had no effect (V5L/L9V), and in others, it made a
large difference (I2L/V5L and I2L/V5L/L9V peptides). To un-
derstand this phenomenon, we determined the crystal struc-
tures of A2I2L/V5L and A2I2L/V5L/L9V.
The crystallographic structures show that the electron den-
sity at the centers of the I2L/V5L and I2L/V5L/L9V peptides is
disordered in most cases (three out of four copies), highly mo-
bile, and poorly fit into the electron density in the last case
(A2I2L/V5L molecule 1, Fig. 2A, and Table III). These data show
that the substitutions at the anchors and at P5 have not de-
creased the flexibility at the center of the peptide, and hence
the binding affinity did not improve substantially.
Based on the crystal structure of A2GP2, we expected the
substituted leucine at the P5 to point down into the peptide
binding cleft under the a2 a helix and to fit into a hydrophobic
pocket there. The closest we came to predicting the orientation
was in the structure of A2I2L/V5L. A comparison of the structure
of GP2 bound to A2 with the structure of A2I2L/V5L shows that
the leucine points in the same direction as valine in molecule 1,
but the side chain points away from the hydrophobic pocket
(Fig. 3A). In molecule 2 of A2I2L/V5L, the leucine is more sol-
vent-exposed and is nowhere close to the pocket (Fig. 3B). One
of the surprises found in this analysis was that there were
many changes seen in the positions of the amino acids past the
P5 residue. Although there is not a great deal of confidence in
the absolute positions of these central residues, it is clear that
the density defines very different paths for the peptide mole-
cule 1 (Fig. 3A). The effect of this substitution on the carboxyl
terminus in molecule 2 is even clearer. The position of the P5
residue alters the position of all the residues from P6 to P9 in
FIG. 2. Averaged omit electron density maps contoured at 1s
show that the central residues of I2L/V5L and I2L/V5L/L9V are
disordered as in the structure of A2GP2. Panel A, averaged omit
map of peptide GP2I2L/V5L in molecule 1 (MOL1) in the asymmetric unit.
Panel B, averaged omit map of peptide molecule 2 (MOL2) in the
GP2I2L/V5L asymmetric unit. Panel C, averaged omit map of peptide
GP2I2L/V5L/L9V in molecule 1 of asymmetric unit. Panel D, averaged omit
map of peptide GP2I2L/V5L/L9V in molecule 2 of asymmetric unit. All
molecules displayed have A2 removed for clarity, and the maps are
contoured at 1s with a cover radius of 1 Å.
TABLE III
Comparison of main chain temperature factors (B in Å2) and real
space correlation coefficient (RSCC) between peptides GP2, I2L/V5L,
and I2L/V5L/L9V in the two molecules in the asymmetric unit





Molecule 1 Molecule 2
I2L/V5L I2L/V5L/L9V I2L/V5L I2L/V5L/L9V
B RSCC B RSCC B RSCC B RSCC B RSCC
1 13.87 0.88 14.91 0.84 20.54 0.79 9.97 0.85 17.44 0.86
2 15.33 0.85 15.18 0.85 21.10 0.83 11.91 0.83 18.12 0.86
3 19.31 0.90 17.30 0.84 23.12 0.83 17.52 0.81 20.45 0.75
4 24.57 0.86 21.29 0.74 25.46 0.63 24.42 0.79 23.28 0.76
5 30.17 0.68 24.40 0.75 26.30 0.55 29.95 0.63 25.31 0.53
6 33.82 0.39 27.88 0.52 25.60 0.55 32.21 0.58 25.39 0.65
7 31.92 0.67 28.73 0.64 23.23 0.71 32.06 0.64 24.00 0.78
8 27.95 0.75 27.95 0.54 21.20 0.85 30.46 0.72 22.16 0.80
9 23.89 0.87 23.81 0.66 20.22 0.83 31.20 0.69 20.89 0.75
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molecule 2 such that the carboxylate is displaced by 1.0 Å (Fig.
3B). The error associated with this model is 0.31 Å. Interest-
ingly, an examination of the termini of these peptides (except
for one copy of I2L/V5L/L9V) shows high temperature factors
for the carboxyl termini compared with the amino terminus
(Table III). This may reflect the more buried nature of the P1
residue compared with the P9 residue.
The most apparent difference between the structures of GP2
and I2L/V5L/L9V peptides is the position of the leucine side
chain at P5. In A2I2L/V5L/L9V, the leucine points toward solvent
away from A2 and does not interact with any residue of the
peptide binding superdomain regardless of which molecule is
examined (Fig. 3, C and D).
A comparison of the structures of A2I2L/V5L and A2I2L/V5L/L9V
illustrates the types of differences that may occur when chang-
ing anchor residues (Fig. 3, E and F, comparing both molecules
1 or molecules 2). In these peptides, the only difference is a
substitution of the GP2 P9 leucine with valine. The result of the
substitution can be a 90° rotation of the Ca-Cb bond at P5 as
observed in molecule 1 (Fig. 3E). The rotation moves the
leucine from pointing toward the a1 a helix (A2I2L/V5L) to
pointing toward solvent (A2I2L/V5L/L9V). The P5 residue is di-
rectly in the center of the peptide, and based on the co-crystal
structures of pMHC and TCR would directly contact the CDR3
regions of the a and b chains of the TCR. Or the result of this
substitution can be a reordering of the positions of all of the
atoms nearby at positions 7–9 as observed in molecule 2 (Fig. 3F).
These data show that large structural changes may occur by
small homologous substitutions in the center or in the anchors
of the peptide. These structural changes can greatly change
TCR recognition. The observed changes in A2I2L/V5L/L9V and
A2V5L/L9V are significantly larger than those seen previously to
FIG. 3. Substitutions of amino acids in the peptide alter the position of other residues in the peptide. Panel A, superpositioning the
a1a2 peptide binding superdomains of A2GP2 and A2I2L/V5L molecule 1 (MOL1) shows that the central residues are in very different positions as
a result of the double substitution. Panel B, superpositioning A2GP2 and molecule 2 (MOL2) of A2I2L/V5L demonstrates the changes that occur from
positions 6–9 in the peptide as a result of the changes. Panel C, comparisons of GP2 and I2L/V5L/L9V show moderate changes, and most are
focused on the V5L substitution. Panel D, a similar comparison with molecule 2 in I2L/V5L/L9V shows even fewer changes. Panel E, a comparison
of the peptides in I2L/V5L and I2L/V5L/L9V (both molecule 1 (MOL1)) shows alterations at the carboxyl end of the peptide as a result of the change
L9V. Panel F, a similar comparison (with molecule 2) illustrates, as did panel C, that position 5 is altered drastically as a consequence of the L9V
substitution. The figure was generated with GRASP (60).
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change TCR reactivity (22, 56). In particular, changes as small
as a substitution of tyrosine for phenylalanine at P1 can cause
only localized changes about the P1 residue, but significant
changes in T cell recognition (56). These changes are much
more dramatic. Immunization with I2L/L9V peptide generates
small but reproducible CTL reactivity in A2Kb transgenic mice.
Similarly, we are able to generate small responses to I2L/V5L/
L9V, but we are unable to generate any responses to the I2L/
V5L or V5L/L9V peptides (data not shown). These CTL data
are not significant in themselves, but they confirm the not
unexpected idea that TCR recognition is different with respect
to these peptides.
In summary, the data presented here show that substitu-
tions in the center of a peptide bound to class I MHC may affect
the positions of all of the residues within the peptide. In addi-
tion, small homologous substitution in the anchor residues can
dramatically alter the TCR-contacting residues. Clearly, the
presence of substituted residues may alter the positions of
nearly all of the other residues even when the substitution is a
minor homologous substitution as is seen in the case of pep-
tides I2L/V5L and I2L/V5L/L9V. These types of changes were
implicated previously in a study of H-2Kb with a panel of
antibodies (57) which showed unexpected changes in antibody
reactivity with a series of peptide substitutions. Similarly, ho-
mologous amino acid changes in TCR-contacting residues show
greatly changed reactivity (58). This may be explained in terms
of a change in the affinity between the MHC-peptide complex
and the TCR but could also be the result of secondary changes
in the peptide conformation as observed here. Examinations of
clones induced by immunization of anchor-substituted APL in a
clinical trial showed large differences in the set of T cells
expanded compared with immunization with tumor-infiltrat-
ing lymphocytes (59). These data are surprising because sub-
stitutions have been shown to have very limited effects on the
path of the peptide (56).2 One difference between those studies
and these data is the relative binding affinity of the peptides
studied. GP2 is a poor-binding peptide, and the others bind
much better. Perhaps in the case of weak affinity, substitutions
have a more dramatic effect. This may have important impli-
cations in cancer immunotherapy because most peptides stud-
ied are of low affinity (41).
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